ProCE Banner Activity

PARP Inhibitor/AR Pathway Inhibitor Combination Approaches in Prostate Cancer

Slideset

Download this slideset from a live symposium to learn more about the latest evidence and approvals for PARP inhibitor/AR pathway inhibitor combinations in prostate cancer.

Released: January 24, 2024

Share

Faculty

Neeraj Agarwal

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA